Viropro Inc. Signs R&D Contract with Intas Biopharmaceuticals of India

Montreal-based Viropro Inc., through its subsidiary Viropro International Inc, signed a contract to develop and produce an undisclosed therapeutic protein with Intas Biopharmaceuticals Limited (IBPL), a bio pharmaceutical company in India. The development contract and a consultancy contract signed in parallel will provide Viropro with product development and licensing revenues of US$2.14 million over the next two years. As mutually agreed to by IBPL and Viropro, the respective companies will retain the IP rights throughout the term of the agreement. Viropro is a biopharmaceutical company specializing in the transfer of its technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases.